Actively Recruiting
Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer
Led by European Institute of Oncology · Updated on 2024-08-05
79
Participants Needed
1
Research Sites
395 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase I/II, single-arm and open-label single-centre clinical trial with the aim to test the feasibility, safety and the efficacy, in terms of complete pathological response, of preoperative ablative radiotherapy in single fraction for selected breast cancer patients.
CONDITIONS
Official Title
Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically proven unifocal adenocarcinoma
- Tumor stage T1-T2
- Tumor size up to 2.5 cm
- No cancer spread to lymph nodes (cN0)
- Age 18 years or older
- Good general health (ECOG 0-2)
- Planned breast-conserving surgery
- Provided written informed consent
You will not qualify if you...
- Tumor located close to skin or chest wall
- Pure non-invasive tumor
- Prior radiation therapy to the chest
- Received neoadjuvant chemotherapy
- Collagen or connective tissue diseases
- Blood clotting or autoimmune disorders
- Previous cancers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IEO, European Institute of Oncology IRCCS
Milan, Italy, 20141
Actively Recruiting
Research Team
M
Maria Cristina Leonardi, MD
CONTACT
A
Anna Morra, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here